Lee Greenberger Discusses Blood Cancer Research and the Leukemia and Lymphoma Society
Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses how the society contributes to blood cancer research.
Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses how the society contributes to blood cancer research.
The Leukemia & Lymphoma Society recently passed the $1 billion mark in research investment, Greenberger said. The society currently has 320 active programs available.
The journey from a laboratory discovery to a therapy that can control disease takes about 10 years. Sustained funding is needed in order to make progress in this field, Greenberger says, and the society’s volunteers, advocates, and cancer patients step up in order to make progress in the field happen.
To learn more about The Leukemia & Lymphoma Society, visit www.lls.org.
Shared Model of Care Post-HCT Offers Safe Follow-Up, Reduces Patient Burden
Published: March 19th 2025 | Updated: March 19th 2025Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.
